Farrell Peter C sold 970 ResMed Inc shares at $234.73 per share on September 2, 2026, in a transaction recorded under code S. The director’s reported ownership after the sale was 51,803 shares, giving investors the post-transaction holding alongside the sale details.
Key Highlights
- The transaction took place on September 2, 2026.
- Farrell Peter C was identified as a director of ResMed Inc.
- The transaction carried code S.
Farrell Peter C sold 970 ResMed Inc (NYSE: RMD) shares at $234.73 per share, leaving reported ownership of 51,803 shares. The transaction occurred on September 2, 2026, and involved ResMed Inc.
ResMed Director’s Share Transaction The transaction was recorded under code S.
The reported 51,803 shares represent his ownership after the sale. The per-share price for the transaction was $234.73. The transaction involved 970 shares. The ownership figure is reported separately from the shares sold, showing the director’s remaining ResMed holding after the transaction. The record identifies Farrell Peter C as the individual associated with both the sale and the post-transaction ownership figure.
FAQs
Q: How many ResMed shares did Farrell Peter C sell?
A: Farrell Peter C sold 970 ResMed Inc shares at $234.73 per share on September 2, 2026. He was identified as a ResMed director.
Q: What was Farrell Peter C’s remaining ResMed stake?
A: Farrell Peter C held 51,803 ResMed Inc shares after the transaction. The filing reports this as his ownership following the sale of 970 shares on September 2, 2026.
Q: What transaction code was used for Farrell Peter C’s ResMed share sale?
A: The ResMed insider transaction was recorded under code S. The filing identifies Farrell Peter C’s sale of 970 shares at $234.73 per share on September 2, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.